News
-
-
PRESS RELEASE
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
Jaguar Health's crofelemer shows promise in reducing TPN needs for MVID and SBS-IF patients. Investor webcast to review proof-of-concept study results presented at ELITE PED-GI Congress -
-
PRESS RELEASE
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health investor webcast to review crofelemer impact on MVID and SBS-IF patients. No approved treatments for MVID, study presented by Dr. Miqdady at ELITE PED-GI Congress -
-
PRESS RELEASE
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Jaguar Health to host investor webcast on crofelemer's impact on MVID and SBS-IF patient experience, with results of investigator-initiated trial by Dr. Miqdady presented at ELITE PED-GI Congress in Abu Dhabi -
-
PRESS RELEASE
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a plant-based prescription drug, granted Orphan Drug Designation by FDA & EMA for treating rare pediatric diseases, including short bowel syndrome (SBS) & microvillus inclusion disease (MVID). Study presented at ELITE PED-GI Congress -
-
PRESS RELEASE
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Jaguar Health's crofelemer shows significant results in breast cancer patients for prophylaxis of diarrhea. Late-breaker abstracts on responder analysis and oral mucositis survey results accepted for MASCC's 2025 Annual Meeting
